Patients with rheumatoid arthritis (RA) and a history of cancer had a similar risk of cancer recurrence regardless of whether or not they received anti-TNF therapy in a Swedish population-based cohort study. Of the 467 patients with RA who started anti-TNF therapy a mean of 7.9 years after cancer diagnosis, 9% had cancer recurrence (mean follow-up 5.3 years) compared with 7.2% of matched patients with RA and a history of cancer who did not receive any form of biologic therapy (n = 2,164; mean follow-up 4.3 years). This difference was not statistically significant (HR 1.06, 95% CI 0.73–1.54).
References
Original article
Raaschou, P. et al. Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: A nationwide population-based cohort study. Ann. Intern. Med. https://doi.org/10.7326/M17-2812 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Anti-TNF therapy not linked to cancer recurrence. Nat Rev Rheumatol 14, 560 (2018). https://doi.org/10.1038/s41584-018-0084-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0084-7
